Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.

Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

[powerpress]

Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

Acquired Resistance Forum Video #7: Speakers from videos #5 and #6 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.

[powerpress]

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.

[powerpress]

Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies.

[powerpress]

Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West. 

[powerpress]

Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.

[powerpress]

Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses.